Global Ligases Enzyme Market Size study & Forecast, by Product (Quick Ligase, T4 DNA Ligase, E. Coli DNA Ligase, and others), by Source (Archaebacterium, Escherichia Coli, Thermus Thermophilus, Pyrococcus Furiosus), by Application (Molecular Cloning, Liga

Global Ligases Enzyme Market Size study & Forecast, by Product (Quick Ligase, T4 DNA Ligase, E. Coli DNA Ligase, and others), by Source (Archaebacterium, Escherichia Coli, Thermus Thermophilus, Pyrococcus Furiosus), by Application (Molecular Cloning, Ligation Mediated PCR, Mutation Detection and others), by End User (Research Laboratories and Institutions, Pharmaceutical and Biopharmaceutical Companies, Diagnostic Laboratories) and Regional Analysis, 2023-2030

Global Ligases Enzyme Market is valued at approximately USD XX million in 2022 and is anticipated to grow with a healthy growth rate of more than 6.2% over the forecast period 2023-2030. Enzymes are biological catalysts that quicken chemical processes, particularly those that take place inside an organism's body. Ligases are a particular class of enzymes that hasten the fusion of two big molecules, such as DNA. These enzymes are widely employed in gene synthesis, cloning, mutation detection, and next-generation sequencing. Enzymes for DNA ligases are also employed to address human dysfunctions and deficiencies. The market for ligases enzymes is expanding as a result of increased research efforts and R&D expenditures to create ligases as potential targets for cancer therapy. Additionally, as ligases are used in the identification of infectious illnesses and birth mutations, an increase in the prevalence of infectious diseases and birth genetic abnormalities is anticipated to fuel market expansion.

The increasing prevalence of various infectious diseases and genetic birth disorders due to its potential diagnostic and therapeutic properties. According to the WHO in 2022, an estimated 10.6 million tuberculosis cases were recorded globally in 2021. Thus, the rising frequency of TB drives the market for ligase enzymes by increasing the need for accurate and early diagnosis. Additionally, according to WHO statistics released in 2022, between January 24 and February 6, 2022, about 12,368 persons tested positive for influenza viruses, with 8,423 (68.1%) falling under the influenza A category and 3,945 (31.9%) falling under the influenza B category. There were 171 (6.4%) influenza A(H1N1) pdm09 subtypes (H3N2) and roughly 2,483 (93.6%) influenza A viruses overall. Such widespread outbreaks of infectious illnesses are predicted to increase demand for ligase enzymes and boost market expansion. Similar to this, the development of ligases as cancer therapeutic treatments is also anticipated to be one of the major market-driving drivers. Additionally, the presence of many vendors that offer ligase enzymes provides lucrative opportunities. However, the risk of the high sensitivity of the ligase enzyme stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Ligases Enzyme Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to well-established end-user sectors such as molecular biology laboratories, research institutions, and pharmaceutical corporations. For instance, according to CDC statistics in March 2022, TB incidence in the United States grew by 9.4% from 2020 to 2021. In addition, the VDH article published in 2022 said that the incidence rate of TB in Mexico was approximately 20 per 100,000 people per year. Furthermore, the Tand F Journal study released in March 2022 said that the yearly incidence rate of TB among the Canadian population was 4.7 per 100,000 people. Such increasing infectious illness rates are likely to fuel demand for ligase enzymes, adding to market expansion over the forecast period. Anticipated substantial growth in the Asia Pacific region during the forecast period is attributed to noteworthy advancements in technological integration and rapid healthcare development in Japan and China. The presence of robust clinical development frameworks, coupled with increasing research and development activities in emerging economies like Australia and India, presents significant opportunities. This scenario is expected to contribute to the overall market growth in the Asia Pacific region throughout the forecast period.

Major market player included in this report are:
Agilent Technologies Inc.
Arctic Zymes Technologies ASA
Bio-Rad Laboratories Inc.
BLIRT S.A.
Codexis Inc.
F. Hoffmann-La Roche Ltd.
Inspiralis Limited
The Merck Group
New England Biolabs (UK) Ltd.
Promega Corporation

Recent Developments in the Market:
 In June 2022, Nurix Therapeutics Launches Expansion Cohort Evaluating NX-2127 in CLL. Nurix Therapeutics has started an ongoing phase 1 study (NCT04830137) to investigate the immunomodulatory oral BTK inhibitor NX-2127. Patients with chronic lymphocytic leukaemia (CLL) expected to be the focus of this trial, the first of three phase 1b expansion cohorts investigating NX-2121.
 In June 2022, QIAGEN N.V. has disclosed its agreements to secure a 96% majority ownership stake in BLIRT SA (Polish Stock Exchange: BLR), a Gdansk, Poland-based manufacturer specializing in recombinant enzymes for the life science industry. This strategic acquisition of BLIRT by QIAGEN introduces synergistic capabilities, enhancing growth prospects for the enzymes and reagents business.

Global Ligases Enzyme Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Source, Application, End User, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Quick Ligase
T4 DNA Ligase
E. Coli DNA Ligase
Others
By Source:
Archaebacterium
Escherichia Coli
Thermus Thermophilus
Pyrococcus Furiosus
By Application:
Molecular Cloning
Ligation Mediated PCR
Mutation Detection
Others
By End User:
Research Laboratories and Institutions
Pharmaceutical and Biopharmaceutical Companies
Diagnostic Laboratories
By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Agilent Technologies Inc.
Arctic Zymes Technologies ASA
Bio-Rad Laboratories Inc.
BLIRT S.A.
Codexis Inc.
F. Hoffmann-La Roche Ltd.
Inspiralis Limited
The Merck Group
New England Biolabs (UK) Ltd.
Promega Corporation

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.